Catalyst Pharmaceuticals, Inc.
CPRX
주식 순위
#4177
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
주가
$31.49
마지막 동기화: 2026-07-21
시가총액
$3.85B
변동 (1일)
0.00%
변동 (1년)
49.88%
국가
US
거래 Catalyst Pharmaceuticals, Inc. (CPRX)
카테고리
Healthcare
Catalyst Pharmaceuticals, Inc. (CPRX)의 매출
Mar 2026 기준 매출 TTM: $596.96M
Catalyst Pharmaceuticals, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $596.96M입니다. 2023년에 회사는 $398.20M의 수익을 올렸으며 이는 2022년의 $214.20M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Catalyst Pharmaceuticals, Inc.의 수익 기록 (2002 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $596.96M | 21.40% |
| 2024 | $491.73M | 23.49% |
| 2023 | $398.20M | 85.90% |
| 2022 | $214.20M | 52.10% |
| 2021 | $140.83M | 18.27% |
| 2020 | $119.07M | 16.39% |
| 2019 | $102.31M | 20,361.20% |
| 2018 | $500.00K | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | -100.00% |
| 2010 | $488.96K | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 2,014.77% |
US
|
|
| $2.23B | 273.23% |
US
|
|
| $15.74B | 2,537.43% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 908.66% |
NL
|
